Humana Stock And the GLP 1 Shift Retail Investors Should Watch

Direct to consumer GLP-1 weight loss drugs are starting to reshape how money flows through large cap US retail and pharmacy chains. With employers pulling back on coverage, recurring monthly prescriptions are moving closer to the checkout counter and away from traditional insurance channels. That shift could change which companies win on store traffic, loyalty programs and cross selling. This article looks at three large US stocks from a retail and pharmacy screener that are exposed to this GLP-1 trend. The goal is to help you decide whether these setups belong on your watchlist or avoid list.

Genuine Parts (GPC)

Overview: Genuine Parts is a US based distributor of automotive and industrial replacement parts, best known for its NAPA Auto Parts stores and Motion industrial network that supply repair shops, fleets and factories with everything from brake pads and batteries to hoses, bearings and diagnostic tools.

Operations: Genuine Parts generates US$9.7b from North America Automotive, US$6.2b from International Automotive and US$9.2b from its Industrial segment, with revenue spread mainly across the United States, Canada, Europe and Australasia.

Market Cap: US$17.2b

Genuine Parts sits in an interesting spot for investors who want exposure to steady parts demand while keeping an eye on execution risk. The company is leaning on its broad NAPA footprint, digital tools and a planned separation of its Automotive and Industrial businesses to sharpen focus and potentially surface more value, even as recent profit margins and earnings have come under pressure from one off losses, restructuring and higher costs. Debt levels and a dividend that is not well covered by current earnings mean you need to be comfortable with balance sheet and payout risk. If management delivers on cost savings and the separation plan, today’s mixed picture may look very different in a few years.

Genuine Parts appears to be a steady operator whose separation plan and cost cuts could be masking a bigger story. Get the full context on earnings pressure, debt and dividend sustainability in the analysis report for Genuine Parts

Humana (HUM)

Overview: Humana is a US health insurer focused on Medicare Advantage and related products, and it also runs CenterWell, a network of senior primary care clinics, home health services and pharmacy operations that support older adults across their care journey.

Operations: Humana generates about US$139.7b in revenue from its Insurance segment and US$24.7b from CenterWell, with revenue of roughly US$145.8b coming from the United States after eliminations.

Market Cap: US$44.0b

Humana gives you a way to gain exposure to aging demographics, Medicare Advantage and the shift toward value based care, while also tying into the GLP 1 prescription story through CenterWell Pharmacy’s fulfillment role. Recent margin pressure, a large US$713m one off loss and funding that leans heavily on external borrowing highlight areas of risk. Management is pruning underperforming Medicare plans, investing in AI to cut costs and expanding CenterWell clinics and pharmacy capacity. A key consideration is whether these moves are enough to turn today’s thin 0.9% net margin into more durable profitability.

Humana’s margin rebuild story is just getting started, with CenterWell growth and AI driven cost cuts sitting beside that thin 0.9% net margin. See how these moving parts stack up in the analysis report for Humana

Glaukos (GKOS)

Overview: Glaukos is an ophthalmic pharmaceutical and medical technology company that develops devices and drugs to treat glaucoma, corneal disorders like keratoconus and retinal diseases. It supplies eye surgeons and specialists with tools that fit into existing procedures and care pathways.

Operations: Glaukos generates about US$612.8m in revenue from the development and commercialization of ophthalmic therapies, with roughly US$468.5m from the United States and US$144.3m from international markets.

Market Cap: US$9.9b

Glaukos may be worth a closer look if you want exposure to eye health rather than crowded retail pharmacy GLP 1 trends. The company operates at the intersection of aging demographics and under treated glaucoma and corneal disease, with products like iDose TR and Epioxa already contributing to record quarterly revenue. You do need to weigh this against current losses, a high reliance on external funding and recent insider selling. A key consideration is whether the pipeline, payer coverage gains and expanding international footprint justify the premium valuation and funding risk associated with this growth story.

Glaukos sits at the intersection of aging eyes and undertreated disease, yet most of the story still lies in the pipeline and payer coverage. See how this growth arc and funding risk align in the analyst forecasts for Glaukos

The three stocks in this article are only a starting point, since the full Large Cap US Retail and Pharmacy Chains screener uncovered 16 more companies with equally compelling stories in the Large-Cap US Retail and Pharmacy Chains screener. Use Simply Wall St to identify, analyze and filter for the specific catalysts and narratives that matter most to you so you can focus on your highest conviction ideas.

Take Control of Your Investment Journey

If Glaukos or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before The Crowd Moves

Fresh stock ideas can move from quiet to breakout quickly, and the best entry points often vanish once momentum is caught. Scan these under the radar picks now and act early.

• Spot under followed cash generators and stress test them through a curated 55 high quality undervalued stocks before the crowd starts chasing their momentum and compressing your potential entry range.
• Track where automation demand is building and shortlist future industrial heavyweights using a focused 36 robotics and automation stocks while these themes are still flying below most investors’ radars.
• Position ahead of a potential nuclear build out and map suppliers with the targeted 88 nuclear energy infrastructure stocks so you are not reacting after prices have already jumped.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com